drug
(avibactam sodium + ceftazidime)
Marketedupdated 5mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 12, 2026
41 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Jun 15, 2032compositionUS 8969566
- Jun 15, 2032compositionUS 9284314
- Jun 15, 2032compositionUS 9695122
- Aug 12, 2031compositionUS 84710254.9y
- Oct 8, 2030formulationUS 88354554.0y
- Nov 12, 2026formulationUS 761208741d
- Jan 7, 2026compositionUS 7112592
FDA exclusivities (1)
- Jan 26, 2027NPPNew Product (3y)116d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that